Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Healux
Cambridge, England, United Kingdomihealux.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Healx’s lead candidate, HLX‑1502, is in a Phase 2 clinical trial for NF1-associated plexiform and cutaneous neurofibromas. The company is also generating preclinical data on additional compounds identified via its generative AI platform targeting other rare diseases. No approved products yet; focus remains on advancing multiple candidates toward the clinic.
- Therapeutic areas
- DermatologyRare DiseasesNeurologyNephrology
- Modalities
- Small moleculeDrug repurposing (using AI to identify new uses for existing drugs)
- Industry
- Biotech
02
Partnerships
Ono Pharmaceutical Co., Ltd.Ovid TherapeuticsPatient advocacy groups, academic institutions, pharmaceutical companies
Beyond the preview
Go deeper on Healux.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Healux.